一分钟看懂
这是一项关于非小细胞肺癌的I 期 / II 期研究，登记的药物或干预包括Montanide (Registered Trademark) ISA-51 VG Adjuvant；H1299 Cell Lysates；N-803；Ventana PD-L1 (SP263 or SP142) assay，当前状态为已暂停。登记地点显示中国Bethesda有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Montanide (Registered Trademark) ISA-51 VG Adjuvant；H1299 Cell Lysates；N-803；Ventana PD-L1 (SP263 or SP142) assay · I 期 / II 期
登记条件中文摘要
年龄范围：18岁至120岁
登记的基本范围为不限性别，年龄18岁至120岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- National Institutes of Health Clinical Center · Bethesda
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Participant with histologically or cytologically proven Stage IB-IIIA (T2a-T4/N0, T1- T3N1, T1-T2/N2) NSCLC per 8th edition TNM Staging System with no clinical evidence of active disease (NED) or minimal residual disease (MRD) not readily accessible by non-invasive biopsy or resection/radiation following standard therapy. Initial diagnosis must be confirmed by the NIH Laboratory of Pathology.
- * History of PD-L1 expression in cancer cells \< 1% as determined by IHC analysis.
- * Participant must be enrolled within 12 weeks following completion of prior SOC therapy.
- * Participant must have an ECOG performance status of 0-2.
- * Participant must be \>=18 years of age.
- * Participant must be willing to co-enroll on protocol 06C0014 (Prospective Analysis of Genetic and Epigenetic Alterations in Patients with Thoracic Malignancies) allowing for the collection of blood for correlative experiments pertaining to this protocol and related translational research efforts in the Thoracic Surgery Branch.
- * Participant must have evidence of adequate bone marrow reserve, hepatic and renal function as evidenced by the following laboratory parameters (all eligibility assessment/enrollment bloodwork must be done at NIH no more than 2 weeks prior to enrollment):
- * Absolute neutrophil count greater than 1500/mm3
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05642195；登记信息更新于 2026-10-07；本站同步于 2026-10-08，中国中心当前名额未经人工确认。